418 related articles for article (PubMed ID: 37331921)
1. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.
Farag F; Sakalis VI; Arteaga SM; Sihra N; Karavitakis M; Arlandis S; Bø K; Cobussen-Boekhorst H; Costantini E; de Heide M; Groen J; Peyronnet B; Phé V; van Poelgeest-Pomfret ML; van den Bos TWL; van der Vaart H; Harding CK; Carmela Lapitan M; Imran Omar M; Nambiar AK
Eur Urol; 2023 Sep; 84(3):302-312. PubMed ID: 37331921
[TBL] [Abstract][Full Text] [Related]
2. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
Eur Urol; 2021 Apr; 79(4):492-504. PubMed ID: 33402296
[TBL] [Abstract][Full Text] [Related]
3. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
Rai BP; Cody JD; Alhasso A; Stewart L
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
[TBL] [Abstract][Full Text] [Related]
4. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
5. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.
Campbell JD; Gries KS; Watanabe JH; Ravelo A; Dmochowski RR; Sullivan SD
BMC Urol; 2009 Nov; 9():18. PubMed ID: 19930578
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
7. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
8. Bladder training for treating overactive bladder in adults.
Funada S; Yoshioka T; Luo Y; Sato A; Akamatsu S; Watanabe N
Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013571. PubMed ID: 37811598
[TBL] [Abstract][Full Text] [Related]
9. Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(3):1-64. PubMed ID: 23074472
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
11. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence.
Nambiar AK; Arlandis S; Bø K; Cobussen-Boekhorst H; Costantini E; de Heide M; Farag F; Groen J; Karavitakis M; Lapitan MC; Manso M; Arteaga SM; Riogh ANA; O'Connor E; Omar MI; Peyronnet B; Phé V; Sakalis VI; Sihra N; Tzelves L; van Poelgeest-Pomfret ML; van den Bos TWL; van der Vaart H; Harding CK
Eur Urol; 2022 Jul; 82(1):49-59. PubMed ID: 35216856
[TBL] [Abstract][Full Text] [Related]
12. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
[TBL] [Abstract][Full Text] [Related]
13. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
16. Electrical stimulation with non-implanted electrodes for overactive bladder in adults.
Stewart F; Gameiro LF; El Dib R; Gameiro MO; Kapoor A; Amaro JL
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010098. PubMed ID: 27935011
[TBL] [Abstract][Full Text] [Related]
17. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
19. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
[TBL] [Abstract][Full Text] [Related]
20. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.
Mostafaei H; Salehi-Pourmehr H; Jilch S; Carlin GL; Mori K; Quhal F; Pradere B; Grossmann NC; Laukhtina E; Schuettfort VM; Aydh A; Sari Motlagh R; König F; Roehrborn CG; Katayama S; Rajwa P; Hajebrahimi S; Shariat SF
Eur Urol Focus; 2022 Jul; 8(4):1072-1089. PubMed ID: 34563481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
